Incyte Corporation (INCY)

Biopharma with counted research staff. Read November 9, 2026 from the annual report for the period ending December 31, 2025, filed February 10, 2026. Ranked 64 of the 145 Healthcare companies read so far, by the share within reach now.

The filing counts 2,844 employees at December 31, 2025 by function, so the 940 in research and development are read apart at scientific R&D and the sales, medical affairs and operations staff at pharmaceutical manufacturing.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 34% now, 46% at the end of 2027, 50% at the end of 2028, 52% at the end of 2030. By the patterns, the work is about 52% desk work, 15% people work and 33% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 49% of the working time stays with people (conversation, in-person and hands-on work), 44% becomes checking a model's work and 5% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

2,844 employees as of December 31, 2025 (stated). Not stated as a U.S. figure: 70% of employees are in the United States and Canada together, 27% in Europe and 3% in Asia.

The filing: “As of December 31, 2025, we had 2,844 employees, representing an increase of approximately 9% over our 2,617 employees as of the end of the prior year.”

The workforce as industry patterns

What the filing says about the workforce: 2,844 employees at December 31, 2025, up 9% from 2,617: 940 in research and development, 213 in medical affairs, 975 in sales and marketing and 716 in operations support and administrative positions; 70% in the United States and Canada, 27% in Europe and 3% in Asia; employees in Austria, Belgium and Spain under collective agreements.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five. Now is projected from METR's April 2026 measurement and Epoch's November 2026 index.

• Johnson & Johnson (JNJ, 140,800 employees)30% now, 41% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)36% now, 53% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)32% now, 44% by 2028
• Pfizer Inc. (PFE, 75,000 employees)32% now, 44% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)32% now, 44% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)32% now, 44% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)32% now, 44% by 2028
• Amgen Inc. (AMGN, 31,500 employees)32% now, 44% by 2028

What the filing says about AI

8 sentences in the filing name AI. The filing names computational and AI-guided drug discovery among its research capabilities and names artificial intelligence in its risk factors on new technology, social media and increasingly sophisticated cyber attacks.

• “Increasing use of social media and new technology, including artificial intelligence, could give rise to liability, breaches of data security or reputational damage, which could harm our business and results of operations. 6 Table of Contents Item 1.”
• “These include target identification and validation, high-throughput screening, medicinal chemistry, protein sciences and technology, computational and AI-guided drug discovery, structural biology, pharmacology, translational sciences, drug metabolism and pharmacokinetics, bioanalysis, and toxicology assessment.”
• “Malicious cyber attacks are growing in frequency and sophistication, including the use of artificial intelligence, and can be made by groups and individuals with a wide range of motives, including nation states, organized criminal groups, "hacktivists" and others acting with malicious intent.”
• “Increasing use of social media and new technology, including artificial intelligence, could give rise to liability, breaches of data security, or reputational damage.”
• “Additionally, the use of artificial intelligence is increasing in the biopharmaceutical industry.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20235median 1
• Fiscal 20246median 4
• Fiscal 20258median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The U.S. share is not stated apart from Canada.
• The 716 in operations support and administrative positions are a bundled count and stay inside the operating pattern (rule 6).

Source: the company's annual report on EDGAR, accession 0000879169-26-000010, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.